ReviewJournal of mood and anxiety disorders2026
Current themes of AI in mental health: Actionable evidence and guardrails for mood and anxiety care.
Review in Journal of mood and anxiety disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, artificial intelligence (AI) is clinically relevant to mood and anxiety care, but the evidence base is uneven across use cases. This narrative review synthesizes recent literature most relevant to clinicians and investigators. Five themes dominate the current field: patient-facing adjunctive tools, failure modes and safety risks, clinician-facing decision support, passive sensing and measurement infrastructure, and governance. Recent randomized evidence supports a narrow efficacy claim for structured chatbot interventions, with small improvements in depressive and anxiety symptoms and more consistent effects on engagement than on symptom superiority. These studies do not support autonomous psychotherapy, and they do not establish a therapeutic advantage for open-ended large language model systems over more constrained designs. Safety studies, by contrast, identify active concerns: harmful endorsement, weak youth risk assessment, inconsistent crisis handling, and anxiety/OCD reassurance loops. The strongest current clinical signal lies in supervised clinician-facing decision support, where recent trials of AI-assisted antidepressant selection improved treatment persistence and some downstream symptom outcomes. Passive sensing detects behaviorally meaningful signals, but evidence that alert-driven deployment improves care remains insufficient for routine practice. Across stakeholder and policy sources, the most defensible deployment model is human-in-the-loop, stepped, and bounded by explicit handoff rules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.